EyePoint (EYPT) Non Operating Income (2010 - 2026)
EyePoint (EYPT) posted Non Operating Income of $2.3 million for Q1 2026, down 19.78% sequentially from $2.9 million in Q4 2025, and down 35.64% YoY from $3.6 million in Q1 2025.
EyePoint (EYPT) Non Operating Income (2010 - 2026) Analysis & Trends
EyePoint has reported Non Operating Income for 15 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Non Operating Income fell 35.64% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (down 28.79% YoY) and the FY2025 annual result came in at $11.8 million, down 22.04% from the prior year.
- Non Operating Income declined to $2.3 million in Q1 2026 per EYPT's latest filing, from $2.9 million in the prior quarter.
- Over five years, Non Operating Income peaked at $4.0 million in Q1 2024 and troughed at -$2.7 million in Q1 2022.
- A 5-year average of $1.8 million and a median of $2.3 million in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income sank 119.61% in 2022, then surged 8218.18% in 2023.
- Over 5 years, Non Operating Income stood at $283000.0 in 2022, then soared by 726.15% to $2.3 million in 2023, then soared by 68.09% to $3.9 million in 2024, then dropped by 25.65% to $2.9 million in 2025, then fell by 19.78% to $2.3 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $2.3 million, $2.9 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 2.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.91 Mn |
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | 2.92 Mn |
| Sep 30, 2025 | 2.29 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Mar 31, 2025 | 3.64 Mn |
| Dec 31, 2024 | 3.93 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Mar 31, 2024 | 4.04 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Sep 30, 2023 | 1.79 Mn |
| Jun 30, 2023 | -159,000.00 |
| Mar 31, 2023 | 390,000.00 |
| Dec 31, 2022 | 283,000.00 |
| Sep 30, 2022 | -22,000.00 |
| Jun 30, 2022 | -190,000.00 |
| Mar 31, 2022 | -2.69 Mn |
| Dec 31, 2021 | -1.38 Mn |
| Sep 30, 2021 | -1.38 Mn |